Search the web
Welcome, Guest
[Sign Out, My Account]

Friday, February 24 2017 6:38am ET - U.S. Markets open in 2 hours and 52 minutes.
Industry Center - Biotechnology
Industry Center > Biotechnology > Biogen Company Profile
More On This Industry
· Summary
· News
· Leaders & Laggards
· Company Index
·Industry Browser
Related Industries
· Diagnostic Substances
· Drug Delivery
· Drug Manufacturers - Major
· Drug Manufacturers - Other
· Drug Related Products
· Drugs - Generic
Top Industries
·Aerospace/Defense - Major Diversified
·Auto Manufacturers - Major
·Business Software & Services
·Chemicals - Major Diversified
·Communication Equipment
·Diversified Computer Systems
·Diversified Investments
·Drug Manufacturers - Major
·Electric Utilities
·Food - Major Diversified
·Industrial Metals & Minerals
·Major Airlines
·Major Integrated Oil & Gas
·Money Center Banks
·Property & Casualty Insurance
·Semiconductor - Broad Line
·Telecom Services - Domestic
Complete Industry List...
Need more? Get unbiased, in-depth information on public and private companies worldwide.
Biogen Company Profile
With its pipeline full of biotech drugs, Biogen (formerly Biogen Idec) aims to meet the unmet needs of patients around the world. The biotech giant is focused on developing treatments in the areas of immunology and neurology. Its product roster includes best-selling Avonex, a popular drug for the treatment of relapsing multiple sclerosis (MS); Tysabri, a drug treatment for MS and Crohn's disease; Rituxan, a monoclonal antibody developed jointly with Genentech that treats non-Hodgkin's lymphoma and rheumatoid arthritis; and Fumaderm, a psoriasis drug marketed in Germany. Other products include Plegridy for MS and Alprolix for hemophilia B. Founded in 1978, Biogen serves customers in more than 90 countries.
Headlines for Biogen
Teva Is Expected to See a Fall in Its Profit Margins in 2017
- Thu 5:06 pm ET
Here's Why Celgene's Latest Drug Is So Exciting
at Motley Fool - Thu 8:02 am ET
Did Biogen Inc. Shoot Itself in the Foot?
at Motley Fool - Wed 9:15 am ET
‚ÄčTop pharma lobbyist casts Biogen as the anti-Shkreli during drug price Q&A
at - Tue Feb 21
More Headlines...
More on Biogen
Quote Msgs
Chart Insider
News Financials
Profile Analyst Ratings
Contact Information
Address: 225 Binney St
Cambridge, MA 02142-1031
Financial Highlights
Fiscal Year End:December
Revenue (2014):9703.30 M
Revenue Growth (1 yr):40.00%
Employees (2014):7,550
Employee Growth (1 yr):10.20%
Key People
Chairman: Stelios Papadopoulos
Managing Director: Francisco Piccolo
CEO: George A. Scangos
Industry Information
Sector: Healthcare
Industry: Biotechnology
Top Competitors
Bayer Pharma AG
Abbott Laboratories (abt)

Copyright © 2017 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Industry information © 2017 Morningstar, Inc. All Rights Reserved. Company information © 2017 Capital IQ All Rights Reserved. Quotes and other information supplied by independent providers identified on the Yahoo Finance partner page. S&P 500 index provided by Comstock. All rights reserved. Top-Ranked Analyst information © 1999-2017, StarMine Corp. All rights reserved. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, Morningstar, CSI and exchanges) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Yahoo site, a user agrees not to redistribute the information found therein.

Questions or Comments?